Ivan Lieberburg

Ivan Lieberburg, M.D., Ph.D., joined Boxer Capital, LLC in 2009. Prior to joining Boxer, Dr. Lieberburg spent 22 years at Élan Corporation plc, a major drugs firm based in Dublin, Ireland, where his most recent role was Executive Vice President, Corporate Office of Technology and Chief Medical Officer. Other senior positions at Elan that he has held include Chief Scientific Officer and Senior Vice President of Research. Dr Lieberburg has been involved in the basic research, development and/or post-marketing studies of a number of Elan’s products, including Zanaflex®, Diastat®, Mysoline®, Zonegran®, Myobloc®, Permax®, Skelaxin®, Tysabri®, Myocet®, Abelcet®, Prialt®, Maxipime®, Azactam®, as well as numerous preclinical and development programs.

Prior to joining Élan (formerly Athena Neurosciences, Inc.) in 1987, Dr. Lieberburg held faculty positions at Albert Einstein School of Medicine and Mt. Sinai School of Medicine.

Dr. Lieberburg has authored over 100 scientific publications, as well as numerous patents. He has been named to several honors including Rockefeller University Fellow, Public Health Corps Scholar, National Research Service Award, UCSF Kaiser Teaching Award, Hartford Foundation Scholar and McKnight Fellow in Neuroscience. Dr. Lieberburg is a director of Adamas Pharmaceuticals and he sits on the Scientific Advisory Boards of Adamas Pharmaceuticals and the Spinal Muscular Atrophy Foundation.

Dr. Lieberburg received an M.D. from the University of Miami School of Medicine (1980), a Ph.D. in Neurobiology from The Rockefeller University (1976), and an Artium Baccalaureus (A.B.) in Biology from Cornell University (1971). He performed his postdoctoral research at The Rockefeller University (1976-1978) and his medical residency and postdoctoral fellowship at the University of California, San Francisco (1980-1984), where he is presently a Clinical Professor of Medicine and regularly attends on the in-patient medical service. He is board certified in internal medicine and endocrinology/metabolism.